JP2021501220A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501220A5
JP2021501220A5 JP2020544333A JP2020544333A JP2021501220A5 JP 2021501220 A5 JP2021501220 A5 JP 2021501220A5 JP 2020544333 A JP2020544333 A JP 2020544333A JP 2020544333 A JP2020544333 A JP 2020544333A JP 2021501220 A5 JP2021501220 A5 JP 2021501220A5
Authority
JP
Japan
Prior art keywords
methoxy
cyclopropyl
isoxazole
octane
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501220A (ja
JP7212693B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058315 external-priority patent/WO2019089667A1/en
Publication of JP2021501220A publication Critical patent/JP2021501220A/ja
Publication of JP2021501220A5 publication Critical patent/JP2021501220A5/ja
Application granted granted Critical
Publication of JP7212693B2 publication Critical patent/JP7212693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544333A 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしての架橋二環化合物 Active JP7212693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580075P 2017-11-01 2017-11-01
US62/580,075 2017-11-01
PCT/US2018/058315 WO2019089667A1 (en) 2017-11-01 2018-10-31 Bridged bicyclic compounds as farnesoid x receptor modulators

Publications (3)

Publication Number Publication Date
JP2021501220A JP2021501220A (ja) 2021-01-14
JP2021501220A5 true JP2021501220A5 (enExample) 2021-11-11
JP7212693B2 JP7212693B2 (ja) 2023-01-25

Family

ID=64332182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544333A Active JP7212693B2 (ja) 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしての架橋二環化合物

Country Status (19)

Country Link
US (1) US10730863B2 (enExample)
EP (1) EP3704113B1 (enExample)
JP (1) JP7212693B2 (enExample)
KR (1) KR102732835B1 (enExample)
CN (1) CN111295382B (enExample)
AR (1) AR113820A1 (enExample)
AU (1) AU2018360577A1 (enExample)
BR (1) BR112020008457A2 (enExample)
CA (1) CA3079833A1 (enExample)
CL (1) CL2020001138A1 (enExample)
CO (1) CO2020005459A2 (enExample)
EA (1) EA202091063A1 (enExample)
ES (1) ES2964964T3 (enExample)
IL (1) IL274321A (enExample)
MX (1) MX2020004405A (enExample)
PE (1) PE20201170A1 (enExample)
SG (1) SG11202003827YA (enExample)
TW (1) TW201922722A (enExample)
WO (1) WO2019089667A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
AU2019362753A1 (en) 2018-10-05 2021-05-20 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
EA202192275A1 (ru) 2019-02-15 2021-11-03 Бристол-Маерс Сквибб Компани Замещенные амидные соединения, полезные в качестве модуляторов фарнезоидного x-рецептора
CN113677666A (zh) 2019-02-15 2021-11-19 百时美施贵宝公司 作为类法尼醇x受体调节剂的经取代的双环化合物
AU2020221371A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CN110922368B (zh) * 2019-11-29 2022-08-16 扬州工业职业技术学院 一种氯代苯异噁唑氨基苯甲酸衍生物及其制备方法与应用
CN110804025B (zh) * 2019-11-29 2022-02-08 扬州工业职业技术学院 一种卤代苯异噁唑衍生物及其制备方法与应用
ES3014367T3 (en) 2020-01-15 2025-04-22 Inst Nat Sante Rech Med Use of fxr agonists for treating an infection by hepatitis d virus
AU2021246527A1 (en) * 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2021203014A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3204800A1 (en) 2021-01-14 2022-07-21 Raphael Darteil Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
CN115504972B (zh) * 2021-06-22 2024-11-12 广东药科大学 异恶唑类衍生物、其制备方法及其作为药物的用途
CA3267500A1 (en) 2022-09-19 2024-03-28 Basf Se AZOLE PESTICIDE COMPOUNDS
CN117105779A (zh) * 2023-07-18 2023-11-24 河南师范大学 一种5-溴-2-甲酰基苯甲酸甲酯的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
BR9910130A (pt) 1998-04-17 2001-01-09 Kenneth Curry Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
MXPA02004796A (es) 1999-11-12 2007-01-30 Biogen Inc Policicloalquilpurinas como antagonistas del receptor de adenosina.
WO2001079261A1 (en) 2000-04-14 2001-10-25 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors
ATE360614T1 (de) 2001-06-21 2007-05-15 Cesare Casagrande Verbindung für die behandlung von atherosclerotischen und thrombotischen erkrankungen
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
EP1761513A1 (en) 2004-07-01 2007-03-14 Wyeth Tetracyclic compounds as estrogen ligands
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
PT2402002T (pt) 2005-04-08 2018-10-08 Ptc Therapeutics Inc Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドx受容体アゴニスト
KR101470659B1 (ko) 2006-09-07 2014-12-08 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-4-일 유도체
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP2108017A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
CA2690406A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid x receptor agonists
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US20110230493A1 (en) 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
WO2010100142A1 (en) 2009-03-03 2010-09-10 Merck Serono S.A. Oxazole pyridine derivatives useful as s1p1 receptor agonists
JP5460858B2 (ja) 2009-05-05 2014-04-02 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール−ピラゾール誘導体
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β-分泌酶活性之噁二唑化合物及其使用方法
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
UA120740C2 (uk) 2011-04-22 2020-02-10 Сігнал Фармасьютікалз, Елелсі Заміщені діамінокарбоксамідні і діамінокарбонітрильні похідні піримідинів, їх композиції і способи лікування з їх допомогою
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
IN2014DN09346A (enExample) 2012-06-13 2015-07-17 Hoffmann La Roche
JP6099753B2 (ja) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
US9567301B2 (en) 2012-11-02 2017-02-14 Dana-Farber Cancer Institute, Inc. Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors
EP2774919A1 (en) 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
AU2014244482B2 (en) 2013-03-14 2018-01-25 Bristol-Myers Squibb Company Bicyclo [2.2.2] acid GPR120 modulators
TW201605859A (zh) 2013-11-14 2016-02-16 必治妥美雅史谷比公司 作為酪蛋白激酶1δ/ε抑制劑之新穎經取代之吡唑并-哌
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
MX2017008057A (es) * 2014-12-18 2017-09-28 Novartis Ag Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN108602811B (zh) 2016-02-01 2021-11-16 轩竹生物科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
SI3419625T1 (sl) 2016-02-22 2021-08-31 Novartis Ag Postopki za uporabo agonistov FXR
SI3419624T1 (sl) 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017218337A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
WO2018059314A1 (zh) 2016-09-28 2018-04-05 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途

Similar Documents

Publication Publication Date Title
JP2021501220A5 (enExample)
JP3544675B2 (ja) 血管形成阻害活性を有するフタラジン
JP6884102B2 (ja) がんの治療のための化合物
JP2020514267A5 (enExample)
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2006520805A5 (enExample)
RU2481333C2 (ru) Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана
JP5265550B2 (ja) 増殖性疾患の治療に有用なキナーゼ阻害剤
TW202122387A (zh) Mta協同性之prmt5抑制劑
HRP20160539T1 (hr) Antagonisti trpv4
JP2014518214A5 (enExample)
JP2016519096A5 (enExample)
JP2020526556A5 (enExample)
JP2014528479A5 (enExample)
KR20130109210A (ko) Fxr을 조절하기 위한 조성물 및 방법
JP2016172739A5 (enExample)
RU2019118623A (ru) Пирролопиримидины в качестве потенциаторов мвтр
JP2012532931A5 (enExample)
JP2019206577A (ja) 一過性受容体電位a1イオンチャネルの阻害
JP2014525444A5 (enExample)
JP2014530237A5 (enExample)
RU2017105296A (ru) Новые соединения
JP2010515734A5 (enExample)
JP2011519891A5 (enExample)
HRP20171454T1 (hr) Fuzionirani heterociklični spojevi kao modulatori ionskih kanala